In this issue:
- Neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma
- Methotrexate use and skin cancer risk
- Health-related QOL with nivolumab ± relatlimab in untreated melanoma
- Occupational UV exposure
- Anti-PD1 discontinuation in advanced melanoma
- Survival and tumour characteristics of single vs. second primary melanoma
- Ipilimumab 3 mg/kg after metastatic melanoma progression on lower doses
- Lentigo maligna: surgical techniques and presurgical mapping
- Skin cancer surveillance after childhood cancer
- Excision margin and local recurrence/survival in T1a melanoma at critical structures
Please login below to download this issue (PDF)